CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 於2025年10月16日，受託人根據該計劃之條款及條件在市場上購買合共4,496,000股本公司 股份，並為獲選參與者之利益以信託方式持有該等股份。受託人於2025年10月16日所購買 及以信託方式持有之股份詳情如下： | 所購買股份總數： | 4,496,000股股份 | | --- | --- | | 所購買股份佔目前已發行股份總數百分比： | 約0.039 % | | 每股平均價格： | 約9.2698港元 | | 所購買股份之總代價： | 約41,677,000港元 | | 受託人所持股份結餘： | 114,000,000股股份 | 董 事 會 將 不 時 檢 討 ， 並 全 權 酌 情 決 定 擬 根 據 該 計 劃 授 予 獲 選 ...

Core Insights - The "2025 Shanghai International Biopharmaceutical Industry Week" forum successfully held the Shanghai Biopharmaceutical Investment and Financing Summit, focusing on "Diverse Capital Empowering Ecological Strengthening" to explore better combinations for the innovation ecosystem in the biopharmaceutical industry [1][3] Group 1: Event Overview - The summit gathered over 200 professionals from academia, industry, investment, and finance, featuring keynote speeches and roundtable discussions on biopharmaceutical investment and financing [3] - The event was hosted by Shanghai Guotou Company, aiming to enhance source innovation and industry aggregation in the biopharmaceutical sector [1] Group 2: Investment Strategies - Shanghai Guotou Company has invested approximately 6.6 billion yuan in biopharmaceutical sub-funds, focusing on innovative drugs, self-controllable industrial chains, brain-computer interfaces, cell and gene therapies, and synthetic biology [5] - The company emphasizes collaboration with ecological partners to explore innovative models and integrate innovation chains, industry chains, capital chains, and talent chains [5] Group 3: Industry Insights - Professor Hong Bo from Tsinghua University discussed the future of brain-computer interfaces, highlighting advancements and clinical trials involving 32 patients, with plans to submit a clinical trial report by the end of the year [7] - CEO Zou Jianjun of Junshi Biosciences emphasized the need for innovation-driven drug companies to focus on unmet clinical needs and build global capabilities from R&D to commercialization [9] Group 4: Market Trends - Guo Qiushan, President of the Shanghai Biopharmaceutical Innovation Transformation Fund, noted a strong recovery in China's capital market and the increasing importance of domestic pharmaceutical companies and M&A funds in driving innovation [11] - Liang Yijian from Shiyao Group highlighted the significance of early-stage projects and the unique advantages of corporate venture capital (CVC) in enhancing clinical, registration, and market capabilities [13] Group 5: Research and Development - The summit featured the release of the latest research results, including the "Stem Cell Industry Development Blue Book" and "AI Pharmaceutical Industry Development Blue Book," providing insights into technological evolution and industry trends [15] - The event underscored the importance of a supportive regulatory environment and the need for diverse capital to interact positively with innovative enterprises [16]

Core Viewpoint - The "2025 Shanghai International Biopharmaceutical Industry Week" forum focused on "Diverse Capital Empowering Ecological Strengthening" to explore better combinations for the innovation ecosystem in the biopharmaceutical industry, aiming to enhance source innovation and industrial aggregation in Shanghai [1] Group 1: Investment and Funding - Shanghai Guotou Company has committed approximately 6.6 billion yuan to biopharmaceutical sub-funds, with a market selection and investment in 22 sub-funds, achieving a leverage ratio of about 5.5 times [4] - The investment strategy emphasizes innovative drugs and devices, self-controllable industrial chains, brain-computer interfaces, cell and gene therapies, and synthetic biology [4] - The company aims to foster collaboration among ecological partners to integrate innovation, industry, finance, and talent chains [4] Group 2: Technological Innovations - Professor Hong Bo from Tsinghua University discussed the development of brain-computer interface technology, highlighting its evolution and future directions, including expanding indications and enhancing precision [6] - The team behind the brain-computer interface has successfully conducted surgeries on 32 patients, with plans to submit clinical trial reports for the first class III medical device by the end of the year [6] Group 3: Industry Trends and Challenges - CEO Zou Jianjun of Junshi Biosciences emphasized the shift from valuation-driven to value-driven approaches in the innovative pharmaceutical sector, focusing on unmet clinical needs and building global capabilities [8] - The resilience and value reconstruction of the biopharmaceutical industry in China were discussed, noting a strong recovery in the capital market and the increasing importance of domestic pharmaceutical companies in mergers and acquisitions [10] Group 4: Collaborative Ecosystem - Liang Yijian from CSPC shared insights on the value creation journey of corporate venture capital (CVC), emphasizing the importance of clinical value and early-stage project innovation [12] - The latest research results on stem cell and AI pharmaceutical industries were released, providing a comprehensive overview of technological evolution and industry trends [14] Group 5: Future Directions - The roundtable discussion highlighted the need for diverse capital to empower industrial innovation, with a focus on regulatory support and the interaction between capital and innovative enterprises [16] - Shanghai Guotou Company plans to build an innovation ecosystem through a comprehensive fund matrix and collaborative partnerships to support the development of a world-class biopharmaceutical industry [16]

Core Viewpoint - The announcement by the company regarding the acceptance of the new drug application for the injection of Idaglutide α by the NMPA in China marks a significant step in the management of obesity and overweight in adults, emphasizing its potential benefits in weight management and metabolic health [1][3]. Group 1: Product Details - Idaglutide α injection is a recombinant human glucagon-like peptide-1 (hGLP-1) Fc fusion protein that requires weekly administration [3]. - The drug selectively binds and activates GLP-1 receptors, leading to appetite suppression and reduced food intake, which contributes to weight loss [3]. - It also lowers blood glucose levels in a glucose-dependent manner and improves cardiovascular and metabolic indicators [3]. Group 2: Clinical Trial Results - The new drug application is primarily based on a key Phase 3 clinical trial involving overweight adults with at least one weight-related comorbidity [4]. - Results indicated that the product significantly reduced patient weight, waist circumference, blood glucose, blood pressure, and blood lipids compared to a placebo, providing cardiovascular and metabolic benefits [4]. - The safety and tolerability of the product were found to be good, with lower rates of gastrointestinal adverse events and treatment discontinuation due to adverse events [4]. - The dose escalation regimen can reach the target maintenance dose within just four weeks, making it a quick and convenient option for patients [4]. - Currently, two Phase 3 clinical trials for the product in patients with type 2 diabetes are actively progressing, potentially benefiting a larger patient population [4].

Group 1 - The core announcement is that the trustee will purchase a total of 504,000 shares of the company under the share award plan, which will be held in trust for selected participants [1] - Additionally, the trustee is set to acquire 6 million shares of the company as part of the same share award plan [1]

Core Insights - The company, 石药集团 (Stone Pharmaceutical Group), announced the purchase of a total of 504,000 shares under its share award plan, which will be held in trust for the benefit of selected participants [1] Summary by Category - **Share Purchase Details** - The company will acquire 504,000 shares on October 15, 2025, as part of its share award plan [1]

Core Viewpoint - The company, Stone Pharmaceutical Group, announced the purchase of a total of 504,000 shares under its share award plan, which will be held in trust for the benefit of selected participants [1] Group 1 - The shares will be purchased on October 15, 2025, by a trustee according to the terms and conditions of the share award plan [1] - The purchased shares will be held in trust for the benefit of selected participants [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 於2025年10月15日，受託人根據該計劃之條款及條件在市場上購買合共504,000股本公司股 份，並為獲選參與者之利益以信託方式持有該等股份。受託人於2025年10月15日所購買及 以信託方式持有之股份詳情如下： | 所購買股份總數： | 504,000股股份 | | --- | --- | | 所購買股份佔目前已發行股份總數百分比： | 約0.004 % | | 每股平均價格： | 約8.8948港元 | | 所購買股份之總代價： | 約4,483,000港元 | | 受託人所持股份結餘： | 109,504,000股股份 | 董 事 會 將 不 時 檢 討 ， 並 全 權 酌 情 決 定 擬 根 據 該 計 劃 授 予 獲 選 參 與 者 其 認 為 適 合 之 股 份 數 目，以及繼續從市場購買之股份數目。 石 藥 集 團 有 ...

Core Viewpoint - The innovative drug sector experienced a significant rally, with the innovative drug index rising by 2.35% as of the midday close on October 15, 2025, driven by strong performances from various companies [1][2]. Group 1: Market Performance - The innovative drug index (886015.TI) closed at 1366.835, reflecting a gain of 2.35%, equivalent to an increase of 31.422 points [2]. - Notable stock performances included Guangshentang, which surged by 20% to 122.65, and several other companies such as Shutaishen and Anglikang, which saw gains of 14.4% and 10.01%, respectively [2][3]. Group 2: Upcoming Events - The European Society for Medical Oncology (ESMO) conference is set to take place from October 17 to 21, 2025, in Berlin, Germany, where significant clinical research results and data are expected to be disclosed [3][4]. Group 3: Business Development Opportunities - There is growing market anticipation for the release of clinical data from domestic innovative drugs and business development (BD) collaborations, with 83 overseas BD transactions recorded in the first eight months of 2025, totaling 845 billion yuan, marking a 62.81% increase compared to the entire year of 2024 [4]. Group 4: Company Earnings Forecast - Several innovative drug companies are expected to report strong earnings for the third quarter of 2025, with Shengnuo Bio projecting a net profit of 114 million to 140 million yuan, representing a year-on-year increase of 100.53% to 145.10% [5]. - Boteng Co. anticipates a net profit of 73.2 million to 88.2 million yuan, indicating a turnaround from losses, driven by a 17% to 21% increase in revenue [5]. Group 5: Industry Outlook - Analysts express optimism regarding the innovative drug sector, anticipating stabilization and rebound due to upcoming catalysts such as BD and medical insurance negotiations [6]. - Long-term trends indicate that the Chinese pharmaceutical industry has transitioned to new growth drivers, particularly in innovative drugs, which are expected to significantly contribute to the growth of Chinese pharmaceutical companies over the next 5 to 10 years [7].

Core Viewpoint - New Nuo Wei is acquiring an additional 29% stake in Giant Stone Biopharmaceutical Co., Ltd. from its controlling shareholder, Enbi Pu Pharmaceutical Co., Ltd., which will increase its ownership to 80% after the transaction is completed [1][4]. Group 1: Acquisition Details - The acquisition price is set at 1.1 billion yuan, representing a premium of approximately 146% over the assessed value of Giant Stone Biopharmaceutical [6]. - New Nuo Wei previously acquired 51% of Giant Stone Biopharmaceutical for 1.871 billion yuan in early 2024, making it a controlling subsidiary [4][11]. - The transaction does not include any performance commitments from the seller [7]. Group 2: Financial Performance - Giant Stone Biopharmaceutical is currently operating at a loss, with losses of approximately 376 million yuan in the first half of 2025 [2][8]. - New Nuo Wei reported a loss of 2.7461 million yuan in the first half of 2025, marking its first mid-year loss since 2017 [7][9]. - The company's revenue for the first half of 2025 was 1.05 billion yuan, a year-on-year increase of 7.99% [7]. Group 3: Strategic Implications - The repeated acquisitions from the controlling shareholder indicate a strategic shift towards the innovative drug sector, as New Nuo Wei aims to enhance its market position [10][11]. - New Nuo Wei is planning to list in Hong Kong to support its global strategy and improve its international competitiveness [13]. - The company has faced challenges in its operational performance, raising questions about its ability to sustain normal operations post-acquisition [7][9].